IndraLab

Statements

VX-745 inhibits MAPK14. 20 / 20
2 14 2 | 1 1
tas
No evidence text available
tas
No evidence text available
23937569
tas
No evidence text available
22037378
tas
No evidence text available
tas
No evidence text available
19950901
tas
No evidence text available
16945533
tas
No evidence text available
15711537
tas
No evidence text available
18183025
tas
No evidence text available
14667219
tas
No evidence text available
24900264
tas
No evidence text available
23442188
tas
No evidence text available
16750367
tas
No evidence text available
18325768
tas
No evidence text available
19751974
signor
"Our data set represents the most detailed comprehensive assessment of the reactivity of known and clinical kinase inhibitors across the kinome published to date. | The data also show that for at least 15 of the 27 kinases that are the primary, intended targets for the compounds tested and that are represented in the assay panel, selective inhibitors, as assessed by both absolute selectivity across the kinome and selectivity relative to the primary target, are among the 72 tested here."
22037378
drugbank
No evidence text available
24900264
signor
"Vx-745 was reported to be active against several isotypes of p38 mapk, including p38alpha, p38beta and p38gamma"
11892915
drugbank
No evidence text available
10592235
sparser
"Even at 10 nM VX-745 inhibits p38α to some extent, and maximal inhibition is achieved at 500 nM, with the level of p-HSP27 and the p-HSP27/HSP27 ratio now reduced to the basal level seen in the contro[MISSING/INVALID CREDENTIALS: limited to 200 char for Elsevier]"
17659871
eidos
"During initial stages of the study , we verified that VX-745 potently and specifically inhibited p38alpha MAP kinase under our experimental conditions ."
32326654